New York Times interviews our founder, Jennifer Miller, on FDA's clinical trial transparency pilot

The New York Times interviewed our founder, Jennifer Miller, on FDA Commissioner Dr. Scott Gottlieb's clinical trial transparency initiatives. She discussed his new pilot, launched last month, which selects 9 recently-approved drugs, whose sponsors (generally pharmaceutical companies) volunteer to participate, to post portions of Clinical Study Reports (CSRs) from their pivotal trials on FDA's website… Read More

February 12, 2018

Big Data Probably Knows More About You Than Your Friends Do

This week we focused on the ethics of Big Data, publishing an article titled, Big Data Probably Knows More About You Than Your Friends Do, in Leaps Mag. The article discusses the promises and perils of big data and concludes with a way to manage your data wealth.  To read the full article click here. Read More

February 7, 2018

Drs. Oz & Jennifer Miller on the ethics of digital pills

Today, the Dr. Oz Show discussed the 1st FDA approved digital pill, Ability MyCite. The pill has a sensor to digitally track if patients take their medicines. Jennifer Miller, discussed 4 points about the ethics of the new technology on the show.  See the clip, here. First, medication adherence is complex. It involves more than just… Read More

January 29, 2018

CBI's Clinical Data and Disclosure Conference

This week, our President, Jennifer Miller, PhD, will speak at CBI's Clinical Data and Disclosure Conference, which starts tomorrow.  She will review the 2017 drug and company rankings as well as introduce the new data-sharing standards to be added to the next Good Pharma Scorecard.  For more information see our events page. Read More

January 29, 2018

Data-sharing Webinar by Bioethics International

Bioethics International will host a webinar on data-sharing for clinical trials, on February 7, 2018. We will introduce our revised patient-level data-sharing standards to be added to the Good Pharma Scorecard (GPS). We'll also review key feedback from industry and non industry on our previous draft standards. This webinar is mainly for pharmaceutical and biotechnology… Read More

January 4, 2018

Our 2017 Good Pharma Scorecard Rankings are published!

We published our 2017 Good Pharma Scorecard Rankings on December 5th in BMJ open.  The Scorecard shows meaningful progress has been made on several key transparency metrics since the first Scorecard was released in 2015: the proportion of new drugs with all phase 2 or 3 trials disclosed from their NDAs went up from 50%… Read More

December 19, 2017

Dr. Jennifer Miller talks with Dr. Oz about the 1st FDA approved Digital Pill: Abilify MyCite

Today, our Founder, Dr. Jennifer E. Miller, filmed a segment for the Dr. OZ show on the ethics of the first FDA approved Digital Pill: Abilify MyCite.  She discussed how medicine adherence is more complex than just tracking whether a person swallows a pill. Drug costs, whether a patient has transportation to a pharmacy, and even… Read More

December 1, 2017

World Economic Forum, Company Badges and Leaderboard

This week at Bioethics International, we: Participated in the World Economic Forum (WEF) in Dubai. Our Founder, Dr. Jennifer Miller, was appointed to the WEF's  Futures Council. She gave a speech on the ethics of human augmentation. We designed new badges, for companies that score #1 or in the top 5 of the Good Pharma Scorecard.… Read More

November 20, 2017

What Transparency Means to Me, as the Founder of Bioethics International and the Good Pharma Scorecard

As the founder of the nonprofit Bioethics International and the Good Pharma Scorecard, I have been working on developing standards for clinical trial transparency and benchmarking the performance of new drugs and drug companies against those standards. Our goal is to improve ethics, trustworthiness, and patient-centricity/engagement in the development and commercialization of medical products and… Read More

October 26, 2017

BEI kicks off program to define what patient-centricity in pharma means today, w/ patient roundtable

The Patient Roundtable convened patient groups to discuss their key ethics concerns about the pharmaceutical industry and how they define patient-centricity and trustworthiness for the sector. We aim to produce a catalogue of ethics concerns and corresponding standards that may help address perceived problems. Discussions topics include (1) how clinical trials are designed, (2) inclusivity… Read More

October 17, 2017

Expanded Access, interns, and working w patient groups

Bioethics International's top 5 accomplishments this week; we... ...began inviting patient groups to our Patient Roundtable on ethics, trustworthiness and patient-centeredness in pharma to be held in October at the Harvard Club. ...formed and convened our 2018 multi multistakeholder conference planning committee, which includes representatives from Ernst and Young and Scientific American. ...published the results of our study in… Read More

June 26, 2017

2014 GPS transparency rankings submitted to journal, data-sharing standards, new team members

Bioethics International's top 5 accomplishments this week, include: Submitting our 2017 Good Pharma Scorecard (GPS) rankings for review by a medical journal.  The 2017 rankings include a new company ranking to accompany the drug rankings on clinical trial transparency.  We also significantly expanded and refined our methodology since the Harvard Pilot (published in November of 2015… Read More

June 1, 2017

Drug & company rankings, Times Square billboard & conference

BEI is returning to its roots and blogging again.  BEI started as a blog in 2005, called Ethics Illustrated. We'll kick off our blogging with regular updates on our efforts.  This month, we've been: Finishing the clinical trial transparency rankings of drugs approved by the FDA in 2014 and large drug companies. We held our bi-annual meeting with the 25 largest drug companies,… Read More

May 18, 2017